Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26707682 | 0.89 | CYP4F2 (0.46) | ACHETSHRKDM4ECASP6CYP4F2 | |
| SCHEMBL2028886 | 0.87 | ACHE (0.39) | ACHEKDM4ECASP6NOS3NOS1 | |
| SCHEMBL63159 | 0.83 | ACHE (0.62) | ACHETSHRKDM4ECASP6CYP4F2 | |
| SCHEMBL3145457 | 0.78 | ENPP2 (0.50) | TSHRNOS3NOS1NOS2ENPP2 | |
| SCHEMBL15430184 | 0.77 | ACHE (0.31) | ACHE | |
| SCHEMBL2029296 | 0.76 | CYP4A11 (0.46) | TSHRKDM4ECYP4F2CYP4A11 | |
| SCHEMBL16959483 | 0.75 | CYP4F2 (0.52) | ACHETSHRKDM4ECASP6CYP4F2 | |
| SCHEMBL8993656 | 0.75 | ACHE (0.48) | ACHEENPP2 | |
| SCHEMBL3154739 | 0.75 | TSHR (0.50) | ACHETSHRNOS3NOS1 | |
| SCHEMBL20649211 | 0.73 | ACHE (0.53) | ACHETSHRKDM4ECASP6CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483228-B1 | NK1 ANTAGONISTS | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| CN-100506776-C | NK1 antagonists | SCHERING CORP (US) | 2009-07-01 | — | — | CN | disclosed |
| CN-1653025-A | NK1Antagonists | SCHERING CORP (US) | 2005-08-10 | — | — | CN | disclosed |
| US-6878732-B2 | NK1 antagonists | SCHERING CORPORATION (US) | 2005-04-12 | — | — | US | disclosed |
| EP-1483228-A1 | NK1 ANTAGONISTS | SCHERING CORPORATION (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040072854-A1 | NK1 antagonists | SCHERING CORPORATION | 2004-04-15 | — | — | US | disclosed |
| WO-2003078376-A1 | NK1 ANTAGONISTS | SCHERING CORPORATION (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072854-A1 | NK1 antagonists | PROKR1, CRHR1, BDKRB2 | ACHE 1304/4885TSHR 548/4885KDM4E 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.